Aligos Q2 2026 earnings: Licensing revenue narrows the quarterly loss

Aligos Therapeutics (Nasdaq: ALGS) reported Q2 2026 revenue of $27.8 million for the quarter ended June 30, up from $1.0 million a year earlier, while diluted net loss per share narrowed to $0.14 from $1.53. Licensing revenue drove the top-line increase and helped offset higher Phase 2 spending, reducing the net loss to $1.5 million even as R&D expense rose by about 72%.

Core earnings data

Licensing agreements contributed $27.8 million of quarterly revenue, while customer revenue was zero. In Q2 2025, Aligos generated $1.0 million of customer revenue and no licensing revenue.

Operating expenses increased by about 52%, primarily because third-party costs for the pevifoscorvir sodium Phase 2 trial pushed R&D spending higher. Nevertheless, the licensing contribution reduced the operating loss substantially.

Below the operating line, income from the change in fair value of 2023 common warrants increased to $3.0 million from $1.7 million. Aligos recorded $1.3 million of pre-tax income, but a $2.8 million income tax provision resulted in the reported net loss.

Business and pipeline progress

Pevifoscorvir sodium

Aligos completed enrollment in the Phase 2 B-SUPREME study, with 131 participants in the HBeAg-positive cohort and 114 in the HBeAg-negative cohort. Topline data from both cohorts are expected in late Q3 2027.

The drug also received Breakthrough Therapy Designation in China for chronic hepatitis B, adding to its Fast Track Designation from the U.S. Food and Drug Administration. Aligos licensed Greater China development and commercialization rights to Amoytop, receiving a $25 million upfront payment and retaining eligibility for up to $420 million in clinical, regulatory and sales milestones, plus tiered high-single-digit royalties.

ALG-170675

Amoytop received Chinese IND approval for ALG-170675, Aligos’ antisense oligonucleotide candidate for chronic hepatitis B. The approval triggered a $3 million milestone payment that Aligos expects to receive in Q3 2026.

Amoytop is funding development in China and plans to begin a Phase 1 single- and multiple-ascending-dose study. Aligos retains rights outside Greater China and may conduct a Phase 2 study in 2028, potentially including combination treatment with pevifoscorvir sodium.

Licensing economics improve results, but funding remains central

The narrower quarterly loss did not come from lower development spending. Instead, licensing revenue nearly covered $29.7 million of operating expenses, while R&D costs increased because of the ongoing Phase 2 program. The result therefore reflects both pipeline investment and the timing of collaboration economics.

Quarter-end liquidity also differed from reported licensing revenue. Aligos had $30.4 million of cash, cash equivalents and investments at June 30, excluding the $25 million upfront payment received in July, while accounts receivable reached $27.8 million.

The company expects its cash resources to fund planned operations through Q4 2026. The July upfront payment and expected Q3 milestone provide additional non-dilutive capital, but the stated runway remains considerably earlier than the expected late-Q3 2027 B-SUPREME data release.

Risks investors need to watch

• Limited funding horizon: Aligos’ stated operating runway extends through Q4 2026, while its main Phase 2 data are not expected until late Q3 2027.
• Rising clinical costs: R&D expense increased about 72% as third-party spending on the pevifoscorvir sodium trial rose, increasing pressure on liquidity.
• Clinical and regulatory uncertainty: B-SUPREME has completed enrollment, but the efficacy and safety results remain pending, and regulatory designations do not guarantee approval.
• Dependence on Amoytop: China development funding, the expected $3 million payment and potential future milestones depend on the collaboration and achievement of specified development, regulatory and commercial events.
• Earnings quality and variability: The quarter’s results benefited materially from licensing revenue and warrant fair-value income rather than customer revenue or lower recurring operating costs.

Summary

Aligos’ Q2 2026 loss narrowed because licensing revenue offset a substantial increase in clinical development spending. Enrollment completion and regulatory progress moved its hepatitis B pipeline forward, but the main B-SUPREME readout remains more than a year away, making R&D costs, collaboration payments and funding beyond Q4 2026 the primary items to monitor.